La Jolla Pharmaceutical Company Announces Drug Study

Home  /  News & Information  /  Current Page

La Jolla Pharmaceutical Company today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human hepcidin) in patients with hereditary hemochromatosis.   Click for more information: https://globenewswire.com/news-release/2017/12/18/1263403/0/en/La-Jolla-Pharmaceutical-Company-Announces-Initiation-of-Multicenter-Randomized-Phase-2-Clinical-Study-of-LJPC-401-in-Patients-with-Hereditary-Hemochromatosis.html


%d bloggers like this: